Jeremy Booty
Psychiatric/Mental Health · Norwich, CTNPI 1669877189
Payments from drug & device makers
Across 121 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$625
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$272
- Neurocrine Biosciences, Inc.$237
- E.r. Squibb & Sons, L.L.C.$168
- GSK$131
- Vanda Pharmaceuticals Inc.$113
- plus $351 from 11 others
What the payments were for
- Food & beverage$1,85198%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 69 | $625 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $272 |
| Neurocrine Biosciences, Inc. | 7 | $237 |
| E.r. Squibb & Sons, L.L.C. | 4 | $168 |
| GSK | 7 | $131 |
| Vanda Pharmaceuticals Inc. | 3 | $113 |
| Indivior Inc. | 3 | $82 |
| Exact Sciences | 2 | $58 |
| Lilly USA, LLC | 1 | $30 |
| Lundbeck LLC | 1 | $30 |
| Alkermes, Inc. | 1 | $28 |
| Corium, LLC | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $14 |
How this compares
$1,898 in reported general payments places this provider in the 80th percentile of 679 psychiatric/mental health providers in Connecticut.
See all psychiatric/mental health providers in Connecticut →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 33 | $49,170 |
| RexultiBrexpiprazole | 11 | $15,925 |
| BelsomraSuvorexant | 14 | $6,492 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,548 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 13 | $2,155 |
| Trazodone Hcl | 71 | $1,953 |
| Ziprasidone Hcl | 14 | $1,307 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 47 | $1,285 |
| Gabapentin | 85 | $1,153 |
| Methylphenidate Hcl | 12 | $1,079 |
| Lurasidone Hcl | 31 | $1,035 |
| Prazosin Hcl | 32 | $785 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 13 | $780 |
| Clonazepam | 73 | $750 |
| Duloxetine Hcl | 11 | $719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $625 | $49,17033 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $27 | $15,92511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 679 psychiatric/mental health providers in Connecticut.
Other psychiatric/mental health in Norwich
- Hui HuNorwich$19K
- John KempNorwich$9K
- Renee LacadieNorwich$5K
- Cristina MeehanNew Britain$224K
- Samantha MrazBridgeport$87K
- Philip FrickManchester$31K
- Gia SantoroWest Haven$25K
- Donna DraperDanbury$19K
- Zahida SairitupaDanbury$19K
- Patrick GagnonMilford$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.